New Developments in VC Financings -
Selling Your Soul?

CALBIO2012

3/8/2012

Life Sciences

San Francisco Marriott Marquis
55 Fourth Street
San Francisco, CA 94103

Michael J. O'Donnell and Stephen B. Thau

Michael J. O'Donnell and Stephen B. Thau

Speaking Engagement

Funding of the life science sector declined in 2010 and 2011. The remaining funding is increasingly skewed toward follow-on and later stage deals, smaller increments, more strings attached and more risk sharing.

This panel will discuss some emerging new structures and trends in initial and follow-on VC financings, including collaborating with the venture arms of big Pharma which can provide additional funding leverage as well as on-going guidance in developing a program that will be of interest to a Pharma buyer, but at what cost? The panel will also discuss the pros and cons of this emerging structure as well as other recent models for VC financings.

Moderator
  • Michael J. O’Donnell, Partner, Morrison & Foerster
Panel Speakers
  • Gaurav Aggarwal, M.D., Partner, Panorama Capital
  • Jonathan MacQuitty, Ph.D., Partner, Abingworth LLP
  • James Sabry, VP Genentech Partnering, Genentech
  • Stephen Thau, Partner, Morrison & Foerster
  • Samuel S Wu, MD Ph.D., Managing Director, MedImmune Ventures

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2017 Morrison & Foerster LLP. All rights reserved.